Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.

We evaluated CD4 cell counts over a 3(1/2) year period following the initiation of potent antiretroviral therapy (ART) in the Multicenter AIDS Cohort Study. The study population included 314 HIV-infected gay men who provided CD4 cell counts for at least 2 years after the initiation of potent ART. Trends in CD4 cell counts and plasma HIV-RNA were analyzed by regression methods that incorporated the statistical dependencies of outcomes measured over time within individuals. Regardless of CD4 cell count at initiation of potent ART, CD4 cell counts increased significantly (p <.05) in the first 2 years after initiation. However, between 2 and 3(1/2) years after initiation, these counts neither increased nor decreased. The pattern of the proportion with plasma HIV-RNA <400 copies/ml was similar to CD4 cell count (i.e., increased significantly after initiation and plateau in the subsequent 1(1/2) years). The single most important predictor of the steady state CD4 cell count that was maintained between 2 and 3(1/2) years after initiation was the change in plasma HIV-RNA in the first year after initiation of potent ART.

[1]  J. Margolick,et al.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study , 2001, AIDS.

[2]  J. Margolick,et al.  Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.

[3]  J. Phair,et al.  Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. , 2001 .

[4]  P. Easterbrook,et al.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Egger,et al.  Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. , 1999, AIDS.

[6]  N. Foudraine,et al.  Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. , 1999, The Journal of infectious diseases.

[7]  F. Maggiolo,et al.  Changes in plasma HIV-RNA and CD4 lymphocyte counts in patients receiving highly active antiretroviral therapy. , 1999, AIDS.

[8]  R. Paganelli,et al.  Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. , 1999, AIDS.

[9]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[10]  V. Calvez,et al.  Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. , 1999, AIDS.

[11]  J. Castilla,et al.  Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. , 1999, AIDS.

[12]  V. Calvez,et al.  Restoration of the immune system with anti-retroviral therapy. , 1999, Immunology letters.

[13]  D. Levy,et al.  Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[14]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[15]  V. Calvez,et al.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease , 1998, The Lancet.

[16]  S. Levitz.  Improvement in CD4+ cell counts despite persistently detectable HIV load. , 1998, The New England journal of medicine.

[17]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[18]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[19]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[20]  J. Margolick,et al.  Failure of T-cell homeostasis preceding AIDS in HIV-1 infection , 1995, Nature Medicine.

[21]  J. Margolick,et al.  Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[22]  J. Margolick,et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.

[23]  R. Brookmeyer,et al.  Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. , 1987, American journal of epidemiology.